Skip to search formSkip to main contentSkip to account menu

1 ML palivizumab 100 MG/ML Injection [Synagis]

Known as: PALIVIZUMAB 100 mg in 1 mL INTRAMUSCULAR INJECTION, SOLUTION [Synagis], Synagis 100 MG in 1 ML Injection, Synagis 100 MG per 1 ML Injection 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a… 
2012
2012
Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab utilization and respiratory syncytial virus… 
2012
2012
Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab use and respiratory outcomes in high-risk… 
Review
2011
Review
2011
BACKGROUND Respiratory syncytial virus (RSV) is a seasonal infectious disease, with epidemics occurring annually from October to… 
Highly Cited
1998
Highly Cited
1998
Background.Respiratory syncytial virus (RSV) is the leading cause of lower respiratory disease in infants and children. MEDI-493…